Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013

      4Q13 Added 16,059 New Subscribers

      4Q13 Revenue Up 33.3% YOY to RMB133.0 Million

      4Q13 Operating Income Up 45.6% to RMB50.7 Million

      Conference Call to be Held June 19, 2013 at 8:00 a.m. ET


      News provided by

      China Cord Blood Corporation

      Jun 18, 2013, 04:01 ET

      Share this article

      Share this article


      HONG KONG, June 18, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and full year of fiscal year 2013 ended March 31, 2013.

      Fourth Quarter of Fiscal 2013 Highlights

      • Revenues for the fourth quarter of fiscal 2013 increased by 33.3% to RMB133.0 million ($21.4 million) from RMB99.8 million in the prior year period.
      • New subscriber sign-ups reached 16,059.
      • Accumulated subscriber base amounted to 311,982, up 30.1% year-over-year.
      • Gross profit increased by 38.8% to RMB106.1 million ($17.1 million) from RMB76.4 million in the prior year period.
      • Gross margin was 79.8%, an increase from 76.6% in the prior year period.
      • Operating income increased by 45.6% to RMB50.7 million ($8.2 million) from RMB34.8 million in the prior year period.
      • Interest expense amounted to RMB22.1 million ($3.6 million), compared to RMB0.9 million in the prior year period.
      • Net income attributable to the Company was RMB23.0 million ($3.7 million), decreased by 21.2% compared to the prior year period, as a result of increased interest expenses.
      • Operating cash inflow for the quarter amounted to RMB155.1 million ($25.0 million).

      Full Year Fiscal 2013 Highlights

      • Revenues for the full year fiscal 2013 increased by 38.3% to RMB526.1 million ($84.7 million) from RMB380.5 million in the prior year.
      • New subscriber sign-ups reached 72,228 and the accumulated subscriber base expanded to 311,982.
      • Gross profit increased by 42.8% to RMB419.5 million ($67.5 million) from RMB293.8 million in the prior year.
      • Operating income increased by 55.2% to RMB209.3 million ($33.7 million) from RMB134.8 million in the prior year.
      • Interest expense amounted to RMB70.1 million ($11.3 million), compared to RMB3.3 million in the prior year.
      • Net income attributable to the Company amounted to RMB112.4 million ($18.1 million), compared to RMB132.0 million in the prior year.
      • Operating cash inflow for the full year fiscal 2013 was RMB578.6 million ($93.2 million).

      "Fiscal 2013 was a fruitful year concluded with eventful accomplishments," stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.  "We successfully added 72,228 new subscribers to our subscriber base, finishing the year by surpassing our original target by more than 12%, and our growing accumulated subscriber base exceeded the three hundred thousand mark at 311,982.  These accomplishments were made possible by our years of market cultivation efforts and the 'Dragon Year' baby boom.  Aside from setting new records of revenue and operating cash flow, we have also raised our investment in both Guangdong and Shandong as we continue to expand our presence in China.  In addition, we are pleased that our Beijing subsidiary received AABB Accreditation as our commitment toward high quality standards has been recognized, which motivates us to strive for further quality excellence for our Group as a whole."    

      Summary – The Fourth Quarter and Full Year Ended March 31, 2012 and 2013


      Three Months Ended March 31,


      Year Ended March 31,


      2012


      2013


      2012


      2013

      (in thousands)

      RMB


      RMB

      US$


      RMB


      RMB

      US$

      Revenues

      99,778


      133,011

      21,417


      380,490


      526,123

      84,711

      Gross Profit

      76,448


      106,104

      17,085


      293,832


      419,502

      67,544

      Operating Income

      34,842


      50,747

      8,172


      134,843


      209,314

      33,702

      Net Income Attributable to the
      Company

      29,239


      23,028

      3,709


      131,980


      112,447

      18,106

      Earnings per Ordinary Shares 
       - Basic[1] and Diluted (RMB/US$)

      0.40


      0.32

      0.05


      1.79


      1.49

      0.24











      Revenue Breakdown (%)










      Processing Fees

      74.0%


      72.2%



      74.0%


      75.4%


      Storage Fees

      26.0%


      27.8%



      26.0%


      24.6%












      New Subscribers (persons)

      14,336


      16,059



      53,924


      72,228


      Total Accumulated Subscribers (persons)

      239,754


      311,982



      239,754


      311,982













      Summary – Selected Cash Flow Statement Items


      Three Months Ended


      Year Ended


      March 31, 2013


      March 31, 2013

      (in thousands)

      RMB

      US$


      RMB

      US$

      Net cash provided by operating activities

      155,079

      24,969


      578,632

      93,166

      Net cash used in investing activities

      (137,297)

      (22,106)


      (493,717)

      (79,494)

      Net cash (used in)/provided by financing activities

      (2,750)

      (443)


      618,718

      99,620

      Fourth Quarter of Fiscal 2013 Financial Results

      REVENUES.  Revenues increased by 33.3% to RMB133.0 million ($21.4 million) in the fourth quarter of fiscal 2013 from RMB99.8 million in the prior year period, driven by increasing new subscriber sign-ups during the quarter, as well as the strong increase in recurring income from our rising accumulated subscriber base.  

      Revenues generated from storage fees increased to RMB37.0 million ($6.0 million), up 42.3% from RMB26.0 million in the prior year period.  As a result of the expanded subscriber base, revenue generated from storage fees as a percentage of total revenues increased to approximately 27.8%, from 26.0% in the prior year period.  

      Revenues generated from processing fees increased to RMB96.0 million ($15.4 million) due to the increase in new subscribers sign-ups.  Revenues generated from processing fees accounted for 72.2% of total revenues, compared to 74.0% in the prior year period.

      GROSS PROFIT.  Gross profit for the fourth quarter of fiscal 2013 increased by 38.8% to RMB106.1 million ($17.1 million) with gross margin expanded from 76.6% in the prior year period to 79.8%.  Higher gross margin is supported by rising contribution from storage revenues and economies of scale, which exceeded the increase in material and labor costs.

      OPERATING INCOME.  Operating income for the fourth quarter increased 45.6% to RMB50.7 million ($8.2 million) from RMB34.8 million in the prior year period.  With the increase in administrative costs largely being contained, the benefit of rising revenue and gross margin expansion helped to fuel the operating margin expansion from 34.9% in the prior period to 38.2%, however the benefit was also partially offset by increased sales and marketing efforts.  Depreciation and amortization expenses for the fourth quarter were RMB11.3 million ($1.8 million), compared to RMB7.7 million in the prior year period.  

      Research and Development Expenses.  Research and development expenses increased to RMB2.2 million ($0.4 million) compared to RMB2.0 million in the prior year period.  

      Sales and Marketing Expenses.  Sales and marketing expenses for the fourth quarter amounted to RMB26.1 million ($4.2 million).  As a percentage of revenue, it increased to 19.6% in the fourth quarter of fiscal 2013, compared to 16.6% in the prior year period.  The increase in sales and marketing expenses represented more comprehensive marketing efforts and an increase in the Company's sales force, which was consistent with management's expectations and sets the stage for the Company's ongoing market penetration efforts.  

      General and Administrative Expenses.  General and administrative expenses were RMB27.0 million ($4.3 million) compared to RMB23.1 million in the prior year period.  As a percentage of revenue, it decreased to 20.3% in the fourth quarter of fiscal 2013, compared to 23.1% in the prior year period, which was generally consistent with the general and administrative expenses of the Company in the third quarter of fiscal 2013.

      OTHER INCOME AND EXPENSES

      Interest Expense.  Interest expense increased to RMB22.1 million ($3.6 million) from RMB0.9 million in the prior year period.  The increase was largely attributable to the convertible notes issued to KKR China Healthcare Investment Limited ("KKR") and Golden Meditech Holdings Limited ("Golden Meditech").  In the fourth quarter of fiscal 2013, interest expense related to the convertible notes amounted to RMB21.2 million ($3.4 million).

      NET INCOME ATTRIBUTABLE TO THE COMPANY.  Income before income tax for the fourth quarter of fiscal 2013 decreased by 12.1% to RMB33.6 million ($5.4 million) due to higher interest expense recorded in the current quarter.  As a result, net income attributable to the Company for the fourth quarter of fiscal 2013 was RMB23.0 million ($3.7 million), and decreased from RMB29.2 million in the prior year period.  Net margin for the fourth quarter of fiscal 2013 was 17.3%, compared to 29.3% in the prior year period, as a result of higher operating margin offset by higher interest expense incurred for the convertible notes.

      EARNINGS PER SHARE.  The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend.[2]  Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights equal to RMB0.00 ($0.00) for the fourth quarter of fiscal 2013.  Basic and diluted earnings per ordinary share for the fourth quarter of fiscal 2013 were RMB0.32 ($0.05).

      LIQUIDITY.  As of March 31, 2013, the Company had cash and cash equivalents of RMB1,494.1 million ($240.6 million) compared to RMB794.3 million as of March 31, 2012.  The Company had total debt of RMB801.8 million ($129.1 million) as of March 31, 2013.  Operating cash inflow for the fourth quarter of fiscal 2013 amounted to RMB155.1 million ($25.0 million), representing a significant growth from RMB102.2 million in the prior year period.

      Full Year Fiscal 2013 Financial Results

      For the full year fiscal year 2013, total revenues increased by 38.3% to RMB526.1 million ($84.7 million) from RMB380.5 million in the prior year.  The increase was largely attributable to the significant increase in new subscribers during the "Dragon Year" baby boom and the expansion of the Company's accumulated subscriber base to 311,982 subscribers.  Similarly, revenues related to processing fees and storage fees grew by 40.9% and 30.8%, respectively.  Gross profit increased by 42.8% to RMB419.5 million ($67.5 million) from RMB293.8 million in the prior year, and operating income increased by 55.2% to RMB209.3 million ($33.7 million) from RMB134.8 million in the prior year. Interest expense increased to RMB70.1 million ($11.3 million) from RMB3.3 million in the prior year, and the increase was largely attributable to the convertible notes issuances during fiscal 2013.  As such, income before income tax grew 4.3% to RMB158.2 million ($25.5 million), from RMB151.6 million in the prior year.  Income tax expense was lower in fiscal 2012 because the Company recorded a tax write-back due to the High and New Technology Enterprise tax status of both Beijing and Guangdong subsidiaries during fiscal 2012, no such write-back was recorded during fiscal 2013. Combining the effects of higher interest expense and lack of tax write-back in fiscal 2013, net income attributable to the Company for the fiscal 2013 amounted to RMB112.4 million ($18.1 million).  Basic and diluted earnings per share attributable to ordinary shares were RMB1.49 ($0.24).  The calculation of basic and diluted earnings per share has taken into consideration the effect of the participating rights in any Excess Cash Dividend[2] of RMB0.08 ($0.01) for fiscal 2013.  Net cash provided by operating activities for full year of fiscal 2013 was RMB578.6  million ($93.2 million), up from RMB353.9 million in the prior year due to higher adoption rates regarding upfront payment option and the increase in new subscriber sign-ups.

      Ms. Zheng stated, "Moving away from the Year of the Dragon and entering fiscal 2014, we expect to experience both challenges and opportunities.  As the Chinese market gradually resumes lower normalized birth trends, we anticipate some near-term pressure to subscriber growth rates.  Consequently, our near-term priority is to penetrate the Guangdong market by adding new storage capacity in the region and accelerating the development and renovation process with respect to the new Zhejiang storage facility." 

      "As the Company is a premium cord blood banking operator, consistent with our pricing strategy to date and pursuit of high quality standings, we have decided to readjust our prices by increasing the processing fee to RMB6,800 from RMB5,800 and gross annual payment to RMB980 from RMB620 across Beijing municipality, Guangdong province and Zhejiang province.  This initiative will allow us to maximize profitability and offset rising production costs.  We remain dedicated to our China expansion strategy by deepening our penetration into our local territories while also pursuing new opportunities in other regions of China where we do not currently serve.  We continue to build on our favorable market position and industry trend to better serve the needs of our customers and drive improved performance for our shareholders." Ms. Zheng concluded.

      [1] The terms of the convertible notes issued to KKR and Golden Meditech provide KKR and Golden Meditech with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration the effect of such participating rights equal to RMB0.00 ($0.00) and RMB0.08 ($0.01) for the three months and year ended March 31, 2013, respectively.


      [2] "Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

      Conference Call

      The Company will host a conference call at 8:00 a.m. ET on Wednesday, June 19, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com.  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 73748995.

      About China Cord Blood Corporation

      China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

      Safe Harbor Statement

      This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date of this press release, and the Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results, unless required by law.

      The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

      This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending March 31, 2013 were made at the noon buying rate of RMB6.2108 to $1.00 on March 29, 2013 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

      For more information, please contact:

      China Cord Blood Corporation
      Investor Relations Department
      Tel: (+852) 3605-8180
      Email: [email protected]

      ICR, Inc.
      Mr. William Zima
      Tel: (+86) 10-6583-7511
      U.S. Tel: (646) 405-5185
      Email: [email protected]

      CHINA CORD BLOOD CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      As of March 31, 2012 and 2013






      March 31,


      March 31,


      2012


      2013


      RMB


          RMB


        US$


      (in thousands except share data)







      ASSETS






      Current assets






      Cash and cash equivalents

      794,311


      1,494,099


      240,565

      Accounts receivable, less allowance for doubtful accounts

      (March 31, 2012: RMB13,916; March 31, 2013: RMB14,112)

      79,012


      73,076


      11,766

      Inventories

      6,666


      10,265


      1,652

      Prepaid expenses and other receivables

      11,561


      11,602


      1,868

      Trading securities

      354


      -


      -

      Debt issuance costs

      -


      3,678


      592

      Deferred tax assets

      5,268


      5,454


      878

      Total current assets

      897,172


      1,598,174


      257,321

      Property, plant and equipment, net

      267,862


      468,272


      75,397

      Non-current prepayments

      2,863


      212,633


      34,236

      Non-current accounts receivable, less allowance for doubtful accounts

      (March 31, 2012: RMB38,628; March 31, 2013: RMB36,361)

      254,236


      249,370


      40,152

      Inventories

      34,651


      39,730


      6,396

      Intangible assets, net

      129,791


      125,170


      20,154

      Available-for-sale equity securities

      98,199


      88,404


      14,234

      Other investment

      134,363


      189,129


      30,452

      Debt issuance costs

      -


      11,667


      1,879

      Deferred tax assets

      5,013


      3,727


      600

      Total assets

      1,824,150


      2,986,276


      480,821







      LIABILITIES






      Current liabilities






      Bank loan

      45,000


      50,000


      8,050

      Accounts payable

      6,343


      9,890


      1,592

      Accrued expenses and other payables

      33,351


      84,006


      13,527

      Deferred revenue

      106,110


      172,328


      27,747

      Amounts due to related parties

      360


      11,241


      1,810

      Income tax payable

      5,943


      4,983


      802

      Total current liabilities

      197,107


      332,448


      53,528

      Convertible notes

      -


      751,781


      121,044

      Non-current deferred revenue

      306,534


      530,258


      85,377

      Other non-current liabilities

      60,420


      107,158


      17,254

      Deferred tax liabilities

      24,462


      23,168


      3,730

      Total liabilities

      588,523


      1,744,813


      280,933







      EQUITY






      Shareholders' equity






      Ordinary shares






      - US$0.0001 par value, 250,000,000 shares authorized, 73,140,147
        shares issued and outstanding as of March 31, 2012 and 73,140,147
        shares issued and 73,003,248 shares outstanding as of
       
      March 31, 2013

      50


      50


      8

      Additional paid-in capital

      865,654


      798,221


      128,522

      Treasury stock, at cost (March 31, 2012: nil; March 31, 2013 :






      136,899 shares)

      -


      (2,815)


      (453)

      Accumulated other comprehensive income

      26,057


      18,256


      2,939

      Retained earnings

      310,973


      423,420


      68,175

      Total shareholders' equity

      1,202,734


      1,237,132


      199,191

      Non-controlling interests

      32,893


      4,331


      697

      Total equity

      1,235,627


      1,241,463


      199,888

      Total liabilities and equity

      1,824,150


      2,986,276


      480,821







      CHINA CORD BLOOD CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

      For the Three Months and Year ended March 31, 2012 and 2013






      Three months ended March 31,


      Year ended March 31,


      2012


      2013


      2012


      2013


      RMB


      RMB


      US$


      RMB


      RMB


      US$


      (in thousands except share data)













      Revenues

      99,778


      133,011


      21,417


      380,490


      526,123


      84,711

      Direct costs

      (23,330)


      (26,907)


      (4,332)


      (86,658)


      (106,621)


      (17,167)

      Gross profit

      76,448


      106,104


      17,085


      293,832


      419,502


      67,544

      Operating expenses












      Research and development

      (1,953)


      (2,249)


      (362)


      (7,615)


      (8,459)


      (1,362)

      Sales and marketing

      (16,567)


      (26,116)


      (4,205)


      (61,678)


      (93,684)


      (15,084)

      General and administrative

      (23,086)


      (26,992)


      (4,346)


      (89,696)


      (108,045)


      (17,396)

      Total operating expenses

      (41,606)


      (55,357)


      (8,913)


      (158,989)


      (210,188)


      (33,842)

      Operating income

      34,842


      50,747


      8,172


      134,843


      209,314


      33,702

      Other income/(expense), net












      Interest income

      3,411


      4,002


      644


      13,432


      15,064


      2,425

      Interest expense

      (896)


      (22,070)


      (3,553)


      (3,287)


      (70,097)


      (11,286)

      Exchange gain/(loss)

      33


      (25)


      (4)


      (1,343)


      (984)


      (158)

      Dividend income

      -


      -


      -


      7,217


      4,685


      754

      Others

      823


      924


      149


      737


      203


      33

      Total other income/(expense), net

      3,371


      (17,169)


      (2,764)


      16,756


      (51,129)


      (8,232)

      Income before income tax

      38,213


      33,578


      5,408


      151,599


      158,185


      25,470

      Income tax expense

      (6,597)


      (10,483)


      (1,688)


      (9,634)


      (38,543)


      (6,206)

      Net income

      31,616


      23,095


      3,720


      141,965


      119,642


      19,264

      Net income attributable to non-

      controlling interests

      (2,377)


      (67)


      (11)


      (9,985)


      (7,195)


      (1,158)

      Net income attributable to












         the Company

      29,239


      23,028


      3,709


      131,980


      112,447


      18,106













      Net income per share:












      Attributable to ordinary shares












      - Basic

      0.40


      0.32


      0.05


      1.79


      1.49


      0.24

      - Diluted

      0.40


      0.32


      0.05


      1.79


      1.49


      0.24













      Other comprehensive income












      -  Net effect of foreign currency 
         translation, net of nil tax

      (604)


      2,936


      473


      (1,653)


      1,296


      209

      -  Net unrealized gain/(loss) in
         available-for-sale equity securities,
         net of nil tax

      58,055


      12,023


      1,936


      46,587


      (9,120)


      (1,468)

      Comprehensive income

      89,067


      38,054


      6,129


      186,899


      111,818


      18,005













      Comprehensive income attributable
         to non-controlling interests

      (2,427)


      (67)


      (11)


      (10,282)


      (7,172)


      (1,155)

      Comprehensive income 
         attributable to the Company

      86,640


      37,987


      6,118


      176,617


      104,646


      16,850


      SOURCE China Cord Blood Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.